11:15:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-31 Årsstämma 2024
2024-03-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-02 Ordinarie utdelning BIOSGN 0.00 SEK
2023-03-31 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-06-30 Årsstämma 2022
2022-05-31 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3


ListaFirst North Stockholm
Biosergen är verksamt inom bioteknik. Bolaget är specialiserat inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.
2022-06-28 11:39:03

Biosergen AB held its annual general meeting on June 28, 2022. The meeting was conducted by postal voting only, without any physical attendance. For more detailed information on the resolutions, please refer to the full notice and the complete proposals. The main resolutions passed at the meeting were as follows:

Adoption of the income statements and the balance sheets
The meeting resolved to adopt the income statement and the balance sheet for the parent company as well as the consolidated income statement and the consolidated balance sheet for the group for 2021.

Disposition of the company's earnings
The meeting resolved, in accordance with the board's proposal, to carry forward available funds, to a new account and that no dividend shall be paid for the financial year 2021.

Discharge from liability
The members of the board of directors and the CEO were discharged from liability for the financial year 2021.

Board of directors and auditor
The meeting resolved, in accordance with shareholders' proposal, that the board shall be composed of seven directors without deputies. The meeting further resolved, in accordance with shareholders' proposal, on the re-election of directors Torsten Goesch, Lena Degling Wikingsson, Achim Kaufhold, Mattias Klintemar, Marianne Kock, Hanne Mette Dyrlie Kristensen and Henrik Moltke. Torsten Goesch was re-elected as chairman of the board.

The meeting resolved, in accordance with shareholders' proposal, that fees to the members of the board of directors shall, for a full year, amount to EUR 40,000 to the chairman of the board and EUR 25,000 to each of the other board members elected by the general meeting who are not employed by the company.

The registered accounting firm Öhrlings PricewaterhouseCoopers AB was re-elected as auditor for the period up until the end of the next annual general meeting. It was resolved that remuneration to the auditor shall be paid according to approved invoices.

Resolution on an issue authorisation
The meeting resolved, in accordance with the board's proposal, on an issue authorisation for the board of directors to, on one or more occasions up until the next annual general meeting, resolve on issue of shares, convertibles, warrants, and/or a combination of these, so-called units. Issue can be made with or without deviation from the shareholders' pre-emption rights.

This authorisation includes the right to issue shares, convertibles, warrants and/or units, with cash payment, payment by way of set-off or payment by contribution in kind, and otherwise subject to conditions as set out in Chapter 2, section 5, second paragraph 1-3 and 5 of the Swedish Companies Act. Warrants may be issued without consideration.